Trough level-based dose reduction during infliximab maintenance treatment in Crohn's disease.

Trial Profile

Trough level-based dose reduction during infliximab maintenance treatment in Crohn's disease.

Not stated
Phase of Trial: Phase II

Latest Information Update: 20 Sep 2014

At a glance

  • Drugs Infliximab (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Acronyms REDIX
  • Most Recent Events

    • 18 Sep 2014 Status changed from planning to unconfirmed as per Netherlands Trial Registry.
    • 03 Jun 2014 According to the Netherlands Trial Registry, planned number of patients changed from 180 to 54.
    • 03 Jun 2014 According to the Netherlands Trial Registry, planned end date changed from 1 Jun 2016 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top